Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | DRD5 | P21918 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880416 | 1.00 | ACE (0.67) | ACECYP19A1ACHEDRD5MMP3 | |
| SCHEMBL29666098 | 1.00 | ACE (0.67) | ACECYP19A1ACHEDRD5MMP3 | |
| SCHEMBL8243497 | 1.00 | ACE (0.67) | ACECYP19A1ACHEDRD5MMP3 | |
| SCHEMBL26312410 | 0.91 | CYP19A1 (0.57) | ACECYP19A1ACHEMEN1KMT2A | |
| SCHEMBL16265990 | 0.90 | CYP19A1 (0.56) | ACECYP19A1ACHEMEN1KMT2A | |
| SCHEMBL24380346 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL25756464 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL29582353 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL16750308 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL15112500 | 0.88 | ACHE (0.57) | ACECYP19A1ACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106349342-B | Pyridine diindyl and imidazolone butyryl-Val-Phe- Glucosamine, preparation, activity and application | 首都医科大学 | 2019-09-17 | — | — | CN | claimed |
| CN-106317204-A | Pyridinoindoloimidazolonebutyryl-Asp-diglucosamine, and preparation, activity and application thereof | 首都医科大学 | 2017-01-11 | — | — | CN | claimed |
| CN-106279372-A | Double pyrido indole imidazolone-butyryl-Lys-glucosamine, it prepares, activity and application | 首都医科大学 | 2017-01-04 | — | — | CN | claimed |
| CN-103450340-B | The antineoplastic oligopeptide that heterocyclic carboxylic acid is modified, its synthesis, antitumor action and application | Capital Medical University (CN) | 2015-08-05 | — | — | CN | claimed |
| CN-102827307-B | Beta-cyclodextrin-modified tetrahydro-beta-carboline carboxylic acid derivatives, and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2015-06-17 | — | — | CN | claimed |
| CN-103446589-B | Tetrahydro-beta-carbolinyl-3- formyl-diethylenetriamino-beta-cyclodextrin copper complex, and preparation, antithrombotic action and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2015-05-27 | — | — | CN | claimed |
| CN-103450340-A | Heterocyclic carboxylic acid-modified anti-tumor oligopeptides and their synthesis, anti-tumor effects and application | UNIV CAPITAL MEDICAL SCIENCES | 2013-12-18 | — | — | CN | claimed |
| CN-103450338-A | Heterocyclic carboxylic acid-modified thymopentins and their preparation method, anti-tumor effect and use | UNIV CAPITAL MEDICAL SCIENCES | 2013-12-18 | — | — | CN | claimed |
| CN-103450371-A | Tetrahydro-beta-carbolinyl-3-formacyl-diethylenetriamino-beta-cyclodextrins, and preparation, antithrombotic activity and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2013-12-18 | — | — | CN | claimed |
| CN-103446589-A | Tetrahydro-beta-carbolinyl-3- formyl-diethylenetriamino-beta-cyclodextrin copper complex, and preparation, antithrombotic action and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2013-12-18 | — | — | CN | claimed |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | Sutter West Bay Hospitals, dba California Pacific Medical Center and Catholic Healthcare West | 2009-12-03 | — | — | US | claimed |
| US-20060292202-A1 | Drug delivery device | BAUSCH & LOMB INCORPORATED | 2006-12-28 | — | — | US | claimed |
| US-12458627-B2 | Autotaxin inhibitors and uses thereof | DF 2024 IP ACQUISITION, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4026549-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | Sabre Therapeutics LLC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3302490-B1 | AUTOTAXIN INHIBITORS AND USES THEREOF | SABRE THERAPEUTICS LLC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20200339562-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2020-10-29 | — | — | US | disclosed |
| US-20050004169-A1 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2005-01-06 | — | — | US | disclosed |
| US-20040102438-A1 | Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye | DR. GERHARD MANN CHEM.-PHARM. FABRIK GMGH (DE) | 2004-05-27 | — | — | US | disclosed |
| WO-2003014147-A1 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | CUBIST PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| US-5047400-A | Treatment of infection; antitumor agents | ADIR ET CIE (FR) | 1991-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458627-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | ACE 442/4885CYP19A1 2934/4885ACHE 826/4885 |
| US-20050004169-A1 | Podophyllotoxin derivatives | APEH, DAGLA, DPY30 | ACE 4001/4885CYP19A1 1694/4885ACHE 593/4885 |
| US-20200339562-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | ACE 878/4885CYP19A1 2727/4885ACHE 3344/4885 |
| US-20060292202-A1 | Drug delivery device | ALDH1A2, ADRB2, ADRA2B | ACE 913/4885CYP19A1 2588/4885ACHE 71/4885 |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | APEH, DAGLA, DPY30 | ACE 4001/4885CYP19A1 1694/4885ACHE 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.